Permanent Atrial FibrillationBEATNCT07759700
Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial
A study testing LBBA pacing and Conventional pacing in people with Permanent Atrial Fibrillation and Preserved Ejection Fraction, run by Poitiers University Hospital at 1 site in France.
Trial summary
The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a… Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Permanent Atrial Fibrillation, Preserved Ejection Fraction
- What is being tested?
- LBBA pacing and Conventional pacing
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 642 participants
- Where
- 1 siteFrance
- Study dates
- 15 Oct 2026to 14 Aug 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years and <90 years
- Atrial fibrillation requiring ventricular pacing because of
- rapid atrial fibrillation requiring atrioventricular node ablation; or
- slow atrial fibrillation i.e. ≤ 50 bpm on admission ECG).
- Left ventricular ejection fraction ≥50%.
- Affiliated person or beneficiary of the French social security scheme
- Having given their informed consent.
Who cannot join
- Indication for an implantable cardioverter defibrillator.
- Presence of a mechanical tricuspid valve
- Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
- Glomerular filtration rate <40 mL/min/1,73m2 with CKD-EPI formula
- Chronic respiratory failure
- Serious medical condition with life expectancy of <2 years
- Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
- Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Céline DELETAGE, MSc contact
France1 site, 1 recruiting
- Recruiting
CHU Poitiers
Poitiers
Rodrigue GARCIA, Pr, 05 16 60 40 89 ext. +33, rodrigue.garcia@chu-poitiers.fr
About this study
Official title: Left Bundle Branch Area Pacing Versus Conventional Right Ventricular Pacing as Initial Strategy for Patients With Permanent Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction Requiring Cardiac Pacing: an Open-label, Multicenter, Randomized Clinical Trial. - the BEAT Study -
The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.
The main questions it aims to answer are:
Read more
Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?
Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.
Participants will:
Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study
Read the detailed description
The BEAT Study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to compare left bundle branch area pacing with conventional right ventricular pacing as the initial pacing strategy in adults with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an indication for permanent ventricular pacing.
Conventional right ventricular pacing is the standard pacing strategy for patients with bradycardia. The ventricular lead is usually positioned at the right ventricular apex or septum. Although this approach is well established, prolonged right ventricular pacing produces a non-physiological pattern of ventricular electrical activation. The resulting electrical and mechanical dyssynchrony may progressively impair left ventricular function and lead to pacing-induced cardiomyopathy, heart failure, hospitalization, and the need for a subsequent procedure to upgrade the pacing system to biventricular pacing.
Patients with permanent atrial fibrillation who require a pacemaker may be particularly exposed to these complications because they generally have a high burden of ventricular pacing. This applies both to patients with slow atrial fibrillation and to those undergoing atrioventricular node ablation for rapid atrial fibrillation. Although these patients may have preserved left ventricular systolic function at the time of pacemaker implantation, repeated non-physiological ventricular activation could contribute to subsequent deterioration in cardiac function.
Left bundle branch area pacing is a conduction-system pacing technique in which the ventricular lead is advanced through the interventricular septum to stimulate the left bundle branch or the surrounding conduction tissue. By recruiting the heart's intrinsic conduction system, this approach is intended to produce more physiological and synchronous ventricular activation than conventional right ventricular pacing. It may therefore preserve left ventricular function and reduce the clinical consequences associated with long-term ventricular pacing.
Evidence supporting left bundle branch area pacing has increased, particularly in patients with impaired left ventricular function or an indication for cardiac resynchronization. However, long-term randomized evidence remains limited in patients with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an expected high ventricular pacing burden. In particular, the effect of the initial pacing strategy on major clinical events in this population has not been adequately established.
The study hypothesis is that left bundle branch area pacing, compared with conventional right ventricular pacing, will reduce clinically important adverse events over 2 years by limiting pacing-related ventricular dyssynchrony and preventing deterioration in left ventricular function.
A total of 642 participants will be enrolled and randomly assigned in a 1:1 ratio to one of two pacing strategies:
Left bundle branch area pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned within the left bundle branch area through the interventricular septum to capture the cardiac conduction system.
Conventional right ventricular pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned at the right ventricular apex or right ventricular septum.
Randomization will be stratified by participating center and by the indication for pacing: rapid permanent atrial fibrillation requiring atrioventricular node ablation or slow permanent atrial fibrillation. Because the implantation techniques are different and identifiable to the treating clinicians, the study is open label.
Participants will be followed for 24 months after pacemaker implantation. Study assessments will include clinical evaluation, pacemaker interrogation, 12-lead electrocardiography, echocardiography, collection of hospitalizations and cardiac reinterventions, assessment of adverse events, and evaluation of health-related quality of life. Follow-up will include clinical visits approximately 2, 12, and 24 months after implantation and telephone contacts approximately 6 and 18 months after implantation.
Echocardiography will be performed at baseline and at the end of the 2-year follow-up to evaluate changes in left ventricular systolic function and ventricular volumes. Pacemaker interrogation will be used to document device function and the proportion of ventricular pacing. Quality of life will be assessed using the Short Form-36 Health Survey and the Kansas City Cardiomyopathy Questionnaire.
The principal comparison will assess whether left bundle branch area pacing improves the proportion of participants who remain free from all-cause death, unplanned hospitalization for heart failure, and upgrade to biventricular pacing at 2 years. Additional analyses will examine cardiac function, individual clinical events, cardiac reinterventions, device- and procedure-related complications, and changes in quality of life. Unplanned heart failure hospitalizations and upgrades to biventricular pacing will be reviewed by an independent adjudication committee.
The primary analysis will follow the intention-to-treat principle. The study is intended to determine whether a physiological pacing strategy should replace conventional right ventricular pacing as the preferred initial approach for patients with permanent atrial fibrillation, preserved left ventricular function, and a substantial anticipated requirement for ventricular pacing.
- Being tested
- LBBA pacing, Conventional pacing
- Keywords
- atrial fibrillation, preserved ejection fraction, heart failure, pacemaker, left-bundle-branch-area pacing
- Medical subject headings
- Atrial Fibrillation, Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LBBA pacingProcedure or surgery
The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.
Conventional pacingProcedure or surgery
The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.
| Study group | Role | What they receive |
|---|---|---|
| LBBA pacing | Experimental | The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum. Receives: Procedure: LBBA pacing |
| Conventional pacing | Active comparator | The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle. Receives: Procedure: Conventional pacing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of post-implantation adverse events
proportion of post-implantation adverse events, combining all-cause mortality, unplanned hospitalization related to heart failure, and upgrade to biventricular pacing.
Measured: At two years
Secondary outcomes (10)
Left ventricular ejection fraction
Left ventricular ejection fraction assessed with echocardiography
Measured: At 2 years post-implantation.
Left ventricular end-systolic volume
Left ventricular end-systolic volume assessed with echocardiography
Measured: At 2 years post-implantation
Time to composite outcome
Time to the first event between death, unplanned hospitalization related to heart failure, and upgrade to biventricular during the 2-year follow-up period
Measured: Through study completion, an average of 2 years
Unplanned hospitalization related to heart failure
Time to unplanned hospitalization for heart failure
Measured: During the 2-year follow-up perio
All-cause mortality
Time to all-cause death
Measured: During the 2-year follow-up period
Upgrade to biventricular pacing
Time to upgrade to biventricular
Measured: During the 2-year follow-up period
Complications
Proportions of pocket hematoma, pneumothorax, lead dislodgment, pacing threshold elevation, pericardial effusion, pocket/wound infection, systemic infection, lead fracture, diaphragmatic stimulation, or pacemaker syndrome
Measured: During the 2-year follow-up period
Cardiac reintervention
Time to cardiac reintervention for upgrade to biventricular pacing or due to a complication
Measured: During the 2-year follow-up period
Quality of life : Short Form 36 Questionnaire score
Evolution at the Short Form 36 Questionnaire score. Minimum score: 0; Maximum score: 100; A higher score indicates better health-related quality of life.
Measured: Evolution between baseline and 2 years post-implantation
Quality of life : Kansas City Cardiomyopathy Questionnaire score
Evolution at the Kansas City Cardiomyopathy Questionnaire score. Minimum: 0 - worst possible heart-failure-related health status; Maximum: 100 - best possible health status, with fewer symptoms and limitations
Measured: Evolution between baseline and 2 years post-implantation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start15 Oct 2026
- Primary completion14 Oct 2028 (estimated)
- Study completion14 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Permanent Atrial FibrillationStudies of the same condition, open and under way.
- More trials run by Poitiers University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 642 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poitiers University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital, Grenoble, Nouvelles Cliniques Nantaises, Nantes, Centre Hospitalier Universitaire de Besancon, Centre Hospitalier de PAU, Centre Cardiologique du Nord, St Denis, Centre Hospitalier Universitaire de Saint Etienne, Centre Hospitalier Departemental Vendee, Centre Hospitalier Régional d'Orléans, University Hospital, Tours
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07759700
- Sponsor's protocol ID
- BEAT STUDY
- Acronym
- BEAT
- Status last verified
- Oct 2026
- First submitted
- 2 Aug 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Left Bundle Branch Area Pacing Versus Conventional Right Ventricular Pacing as Initial Strategy for Patients With Permanent Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction Requiring Cardiac Pacing: an Open-label, Multicenter, Randomized Clinical Trial. - the BEAT Study -
- ClinicalTrials.gov ID
- NCT07759700
- Acronym / sponsor ID
- BEAT / BEAT STUDY
- Keywords
- atrial fibrillation, preserved ejection fraction, heart failure, pacemaker, left-bundle-branch-area pacing
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 642 participants (estimated)
- Lead sponsor
- Poitiers University HospitalUniversity, hospital or other
- Collaborators
- University Hospital, Grenoble, Nouvelles Cliniques Nantaises, Nantes, Centre Hospitalier Universitaire de Besancon, Centre Hospitalier de PAU, Centre Cardiologique du Nord, St Denis, Centre Hospitalier Universitaire de Saint Etienne, Centre Hospitalier Departemental Vendee, Centre Hospitalier Régional d'Orléans, University Hospital, Tours
- Study start
- 15 Oct 2026 (actual)
- Primary completion
- 14 Oct 2028 (estimated)
- Study completion
- 14 Aug 2030 (estimated)
- First posted
- 12 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.
The main questions it aims to answer are:
Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?
Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.
Participants will:
Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study
Detailed description
The BEAT Study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to compare left bundle branch area pacing with conventional right ventricular pacing as the initial pacing strategy in adults with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an indication for permanent ventricular pacing.
Conventional right ventricular pacing is the standard pacing strategy for patients with bradycardia. The ventricular lead is usually positioned at the right ventricular apex or septum. Although this approach is well established, prolonged right ventricular pacing produces a non-physiological pattern of ventricular electrical activation. The resulting electrical and mechanical dyssynchrony may progressively impair left ventricular function and lead to pacing-induced cardiomyopathy, heart failure, hospitalization, and the need for a subsequent procedure to upgrade the pacing system to biventricular pacing.
Patients with permanent atrial fibrillation who require a pacemaker may be particularly exposed to these complications because they generally have a high burden of ventricular pacing. This applies both to patients with slow atrial fibrillation and to those undergoing atrioventricular node ablation for rapid atrial fibrillation. Although these patients may have preserved left ventricular systolic function at the time of pacemaker implantation, repeated non-physiological ventricular activation could contribute to subsequent deterioration in cardiac function.
Left bundle branch area pacing is a conduction-system pacing technique in which the ventricular lead is advanced through the interventricular septum to stimulate the left bundle branch or the surrounding conduction tissue. By recruiting the heart's intrinsic conduction system, this approach is intended to produce more physiological and synchronous ventricular activation than conventional right ventricular pacing. It may therefore preserve left ventricular function and reduce the clinical consequences associated with long-term ventricular pacing.
Evidence supporting left bundle branch area pacing has increased, particularly in patients with impaired left ventricular function or an indication for cardiac resynchronization. However, long-term randomized evidence remains limited in patients with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an expected high ventricular pacing burden. In particular, the effect of the initial pacing strategy on major clinical events in this population has not been adequately established.
The study hypothesis is that left bundle branch area pacing, compared with conventional right ventricular pacing, will reduce clinically important adverse events over 2 years by limiting pacing-related ventricular dyssynchrony and preventing deterioration in left ventricular function.
A total of 642 participants will be enrolled and randomly assigned in a 1:1 ratio to one of two pacing strategies:
Left bundle branch area pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned within the left bundle branch area through the interventricular septum to capture the cardiac conduction system.
Conventional right ventricular pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned at the right ventricular apex or right ventricular septum.
Randomization will be stratified by participating center and by the indication for pacing: rapid permanent atrial fibrillation requiring atrioventricular node ablation or slow permanent atrial fibrillation. Because the implantation techniques are different and identifiable to the treating clinicians, the study is open label.
Participants will be followed for 24 months after pacemaker implantation. Study assessments will include clinical evaluation, pacemaker interrogation, 12-lead electrocardiography, echocardiography, collection of hospitalizations and cardiac reinterventions, assessment of adverse events, and evaluation of health-related quality of life. Follow-up will include clinical visits approximately 2, 12, and 24 months after implantation and telephone contacts approximately 6 and 18 months after implantation.
Echocardiography will be performed at baseline and at the end of the 2-year follow-up to evaluate changes in left ventricular systolic function and ventricular volumes. Pacemaker interrogation will be used to document device function and the proportion of ventricular pacing. Quality of life will be assessed using the Short Form-36 Health Survey and the Kansas City Cardiomyopathy Questionnaire.
The principal comparison will assess whether left bundle branch area pacing improves the proportion of participants who remain free from all-cause death, unplanned hospitalization for heart failure, and upgrade to biventricular pacing at 2 years. Additional analyses will examine cardiac function, individual clinical events, cardiac reinterventions, device- and procedure-related complications, and changes in quality of life. Unplanned heart failure hospitalizations and upgrades to biventricular pacing will be reviewed by an independent adjudication committee.
The primary analysis will follow the intention-to-treat principle. The study is intended to determine whether a physiological pacing strategy should replace conventional right ventricular pacing as the preferred initial approach for patients with permanent atrial fibrillation, preserved left ventricular function, and a substantial anticipated requirement for ventricular pacing.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LBBA pacing | Experimental | Procedure: LBBA pacingThe LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum. |
| Conventional pacing | Active comparator | Procedure: Conventional pacingThe conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle. |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age ≥ 18 years and <90 years
- Atrial fibrillation requiring ventricular pacing because of
- Left ventricular ejection fraction ≥50%.
- Affiliated person or beneficiary of the French social security scheme
- Having given their informed consent.
Key exclusion criteria (8 listed)
- Indication for an implantable cardioverter defibrillator.
- Presence of a mechanical tricuspid valve
- Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
- Glomerular filtration rate <40 mL/min/1,73m2 with CKD-EPI formula
- Chronic respiratory failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LBBA pacingThe LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum. | Procedure or surgery | LBBA pacing |
| Conventional pacingThe conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle. | Procedure or surgery | Conventional pacing |
Primary outcome
Proportion of post-implantation adverse events
Time frame: At two years
proportion of post-implantation adverse events, combining all-cause mortality, unplanned hospitalization related to heart failure, and upgrade to biventricular pacing.
10 secondary outcomes
Left ventricular ejection fraction
Time frame: At 2 years post-implantation.
Left ventricular end-systolic volume
Time frame: At 2 years post-implantation
Time to composite outcome
Time frame: Through study completion, an average of 2 years
Unplanned hospitalization related to heart failure
Time frame: During the 2-year follow-up perio
All-cause mortality
Time frame: During the 2-year follow-up period
Upgrade to biventricular pacing
Time frame: During the 2-year follow-up period
Complications
Time frame: During the 2-year follow-up period
Cardiac reintervention
Time frame: During the 2-year follow-up period
Quality of life : Short Form 36 Questionnaire score
Time frame: Evolution between baseline and 2 years post-implantation
Quality of life : Kansas City Cardiomyopathy Questionnaire score
Time frame: Evolution between baseline and 2 years post-implantation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Permanent Atrial Fibrillation
Not yet recruitingObservational study
Home Monitor for AA Burden Detection IIT in TWN
Paroxysmal Atrial Fibrillation (PAF), Atrial Flutter
RecruitingObservational study
Patient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation
Atrial Fibrillation (AF), Cardiomyopathy, Secondary
Recruiting
Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillation (AF), Heart Failure and Preserved Ejection Fraction: Heart Rate Regularization Versus Medical Rate Control
Heart Failure With Preserved Ejection Fraction, Atrial Fibrillation, Persistent
RecruitingPhase 2
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
Atrial Fibrillation (AF), Paroxysmal AF
RecruitingPhase 2/3
Caffeine Consumption and Rate Control in Permanent Atrial FIBrillation: The CAFIB Trial
Atrial Fibrillation (AF), Permanent Atrial Fibrillation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Céline DELETAGE, MSc contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing LBBA pacing and Conventional pacing in people with Permanent Atrial Fibrillation and Preserved Ejection Fraction, run by Poitiers University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Rodrigue GARCIA, MD, PhD (+33516604089, sec.rythmologie@chu-poitiers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of post-implantation adverse events (time frame: At two years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.